CohBar, Inc. to Announce Fourth Quarter 2016 Financial Results and Host Conference Call for Shareholders on March 22, 2017
Menlo Park, California – March 3, 2017 – CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will release its fourth quarter 2016 financial results on Wednesday, March 22, 2017 and management will host a conference call for shareholders the same day at 2:00 p.m. (PST).
Conference Call Information:
Date: March 22, 2017
Time: 2:00 p.m. (PST)
Dial-in U.S. and Canada: 1-888-287-5516
Dial-in International: 1-719-457-2683
Conference ID# 3409008
An audio recording of the call will be available beginning at 5:00 p.m. (PST) on March 22, 2017, through 9:00 p.m. (PDT) on March 29, 2017. To access the recording please dial 1-844-512-2921 in the U.S. and Canada or 1-412-317-6671 internationally and reference Conference ID# 3409008.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease (NASH), Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.
For additional company information, please visit www.cohbar.com.
Investor and Media Contact:
(650) 446-7888 Ext. 114